Search Results - "Avanzi, Mauro P"

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial by Jacobson, Caron A, Chavez, Julio C, Sehgal, Alison R, William, Basem M, Munoz, Javier, Salles, Gilles, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Yakoub-Agha, Ibrahim, Oluwole, Olalekan O, Fung, Henry Chi Hang, Rosenblatt, Joseph, Rossi, John M, Goyal, Lovely, Plaks, Vicki, Yang, Yin, Vezan, Remus, Avanzi, Mauro P, Neelapu, Sattva S

“…Most patients with advanced-stage indolent non-Hodgkin lymphoma have multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric…”
Get full text

Ex Vivo production of platelets from stem cells by Avanzi, Mauro P., Mitchell, William Beau

“…Summary Stem cell technology holds great promise for transfusion medicine, and generation of platelets from stem cells would be transformative. Platelet…”
Get full text

Rho kinase inhibition drives megakaryocyte polyploidization and proplatelet formation through MYC and NFE2 downregulation by Avanzi, Mauro P., Goldberg, Francine, Davila, Jennifer, Langhi, Dante, Chiattone, Carlos, Mitchell, William Beau

“…Summary The processes of megakaryocyte polyploidization and demarcation membrane system (DMS) formation are crucial for platelet production, but the mechanisms…”
Get full text

Actin Inhibition Increases Megakaryocyte Proplatelet Formation through an Apoptosis-Dependent Mechanism by Avanzi, Mauro P., Izak, Marina, Oluwadara, Oluwasijibomi E., Mitchell, William Beau

“…Megakaryocytes assemble and release platelets through the extension of proplatelet processes, which are cytoplasmic extensions that extrude from the…”
Get full text

A novel bioreactor and culture method drives high yields of platelets from stem cells by Avanzi, Mauro P., Oluwadara, Oluwasijibomi E., Cushing, Melissa M., Mitchell, Maxwell L., Fischer, Stephen, Mitchell, W. Beau

“…BACKGROUND Platelet (PLT) transfusion is the primary treatment for thrombocytopenia. PLTs are obtained exclusively from volunteer donors, and the PLT product…”
Get full text

Optimizing megakaryocyte polyploidization by targeting multiple pathways of cytokinesis by Avanzi, Mauro P., Chen, Amanda, He, Wu, Mitchell, W. Beau

“…BACKGROUND: Large‐scale in vitro production of platelets (PLTs) from cord blood stem cells is one goal of stem cell research. One step toward this goal will be…”
Get full text

Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors by Nardo, Mirella, Motta, Tatiane C., Colli, Leandro M., Avanzi, Mauro P.

“…The use of immunotherapy in cancer treatment over the past decade has resulted in significant advances and improvements in cancer patients survival with the…”
Get full text

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System by Avanzi, Mauro P., Yeku, Oladapo, Li, Xinghuo, Wijewarnasuriya, Dinali P., van Leeuwen, Dayenne G., Cheung, Kenneth, Park, Hyebin, Purdon, Terence J., Daniyan, Anthony F., Spitzer, Matthew H., Brentjens, Renier J.

“…Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma…”
Get full text

Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma by Avanzi, Mauro P, Brentjens, Renier J

“…Adoptive T-cell therapy with chimeric antigen receptor T cells (CAR-Ts) has produced impressive clinical responses among patients with B-cell malignancies, and…”
Get more information

Ex Vivo production of platelets from stem cells : PLATELETS by AVANZI, Mauro P, MITCHELL, William Beau

Get full text

Rho kinase inhibition drives megakaryocyte polyploidization and proplatelet formation through MYC and NFE 2 downregulation by Avanzi, Mauro P., Goldberg, Francine, Davila, Jennifer, Langhi, Dante, Chiattone, Carlos, Mitchell, William Beau

“…The processes of megakaryocyte polyploidization and demarcation membrane system ( DMS ) formation are crucial for platelet production, but the mechanisms…”
Get full text

IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL) by Jacobson, Caron A., Chavez, Julio C., Sehgal, Alison R., William, Basem M., Munoz, Javier, Salles, Gilles, Casulo, Carla, Munshi, Pashna N., Maloney, David G., Vos, Sven de, Reshef, Ran, Leslie, Lori A., Yakoub-Agha, Ibrahim, Oluwole, Olalekan O., Fung, Henry C., Plaks, Vicki, Yang, Yin, Lee, Jennifer, Avanzi, Mauro P., Neelapu, Sattva S.

“…Here, we report interim results from ZUMA-5, a Phase 2 study of axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients…”
Get full text

Retreatment with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) in Zuma-5 by Chavez, Julio C., Jacobson, Caron A., Sehgal, Alison R., Neelapu, Sattva S., Maloney, David G., Salles, Gilles, William, Basem M., Yang, Yin, Goyal, Lovely, Chou, Justin, Plaks, Vicki, Avanzi, Mauro P.

Get full text

44 - Retreatment with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) in Zuma-5 by Chavez, Julio C., Jacobson, Caron A., Sehgal, Alison R., Neelapu, Sattva S., Maloney, David G., Salles, Gilles, William, Basem M., Yang, Yin, Goyal, Lovely, Chou, Justin, Plaks, Vicki, Avanzi, Mauro P.

Get full text

69 - Primary Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) by Jacobson, Caron A., Chavez, Julio C., Sehgal, Alison R., William, Basem M., Munoz, Javier, Salles, Gilles, Munshi, Pashna N., Casulo, Carla, Maloney, David G., de Vos, Sven, Reshef, Ran, Leslie, Lori A., Yakoub-Agha, Ibrahim, Oluwole, Olalekan O., Fung, Henry, Rosenblatt, Joseph, Rossi, John M., Goyal, Lovely, Plaks, Vicki, Yang, Yin, Lee, Jennifer, Godfrey, Wayne, Vezan, Remus, Avanzi, Mauro P., Neelapu, Sattva S.

Get full text

Primary Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) by Jacobson, Caron A., Chavez, Julio C., Sehgal, Alison R., William, Basem M., Munoz, Javier, Salles, Gilles, Munshi, Pashna N., Casulo, Carla, Maloney, David G., de Vos, Sven, Reshef, Ran, Leslie, Lori A., Yakoub-Agha, Ibrahim, Oluwole, Olalekan O., Fung, Henry, Rosenblatt, Joseph, Rossi, John M., Goyal, Lovely, Plaks, Vicki, Yang, Yin, Lee, Jennifer, Godfrey, Wayne, Vezan, Remus, Avanzi, Mauro P., Neelapu, Sattva S.

Get full text

End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma by Jacobson, Caron A., Locke, Frederick L., Miklos, David B., Herrera, Alex F., Westin, Jason R., Lee, Jennifer, Rossi, John M., Sun, Jennifer, Zheng, Lianqing, Avanzi, Mauro P., Roberts, Zachary J.

“…Axi-cel is a US FDA-approved autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy for treatment of adult patients (pts) with relapsed or…”
Get full text